US Pat. No. 10,426,797

COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ANTI-CD33 IMMUNOTHERAPY

LENTIGEN TECHNOLOGY, INC....

1. An isolated nucleic acid molecule encoding a chimeric antigen receptor (CAR) comprising, from N-terminus to C-terminus:(i) at least one extracellular antigen binding domain comprising a CD33 antigen binding domain encoded by the nucleotide sequence consisting of SEQ ID NO. 1, 3, 5, 7, 9, or 11:
(ii) a transmembrane domain comprising a transmembrane domain of a protein selected from the group consisting of the T-cell receptor (TCR) alpha chain, the TCR betachain, the TCR zeta chain, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137 and CD154, or any combination thereof;
(iii) at least one costimulatory domain comprising a functional signaling domain selected from the group consisting of OX40, CD70, CD27, CD28, CD5, ICAM-1, LFA-1 (CD11a/CD18), ICOS (CD278), DAP10, DAP12, and 4-1BB (CD137), or any combination thereof; and
(iv) an intracellular signaling domain comprising a functional domain selected from the group consisting of a 4-1BB (CD137); CD28, and CD3 zeta signaling domain, or a combination thereof.
US Pat. No. 10,428,333

NON-NATURAL AMINO ACID REPLICATION-DEPENDENT MICROORGANISMS AND VACCINES

Ambrx Inc., La Jolla, CA...

1. A vaccine comprising an attenuated live bacterial or viral cell comprising a non-natural amino acid site-specifically incorporated into an essential gene product required for replication, wherein said cell is capable of replication in the presence of said non-natural amino acid, and has limited or no replication capability in the absence of said non-natural amino acid; and wherein the vaccine induces an immune response or reduces the risk of a bacterial or viral infection to said cell.
US Pat. No. 10,426,798

MODULATABLE SWITCH FOR SELECTION OF DONOR MODIFIED CELLS

Calimmune, Inc., Tucson,...

1. A method of providing benefits of a lymphocyte infusion to a patient in need of treatment thereof comprising:(a) generating HPRT deficient lymphocytes from a donor sample;
(b) positively selecting for the HPRT deficient lymphocytes ex vivo to provide a population of modified lymphocytes; and
(c) administering the population of modified lymphocytes to the patient following an administration of an HSC graft to the patient,
wherein the positive selection comprises contacting the generated HPRT deficient lymphocytes with a purine analog and an inhibitor of xanthine oxidase.
US Pat. No. 10,426,799

METHODS FOR PRODUCTION OF PLATELETS FROM PLURIPOTENT STEM CELLS AND COMPOSITIONS THEREOF

Astellas Institute for Re...

1. A method for producing human megakaryocytes comprising:(a) culturing human pluripotent stem cells under an adherent condition in culture medium that comprises bone morphogenetic protein 4, basic fibroblast growth factor, and vascular endothelial growth factor to form human hemogenic endothelial cells;
(b) culturing the human hemogenic endothelial cells in culture medium that comprises two or more factors selected from thrombopoietin, interleukin-3, and interleukin-6 to form human megakaryocyte progenitors; and
(c) culturing the human megakaryocyte progenitors under a non-adherent culture condition in culture medium that comprises thrombopoietin and one or more factor(s) selected from stem cell factor, interleukin-6, interleukin-9, and a ROCK inhibitor to form human megakaryocytes.
US Pat. No. 10,428,335

YEAST CELLS EXPRESSING TAR DNA-BINDING PROTEIN 43 AND USES THEREFOR

Whitehead Institute for B...

1. A method of identifying a genetic suppressor or enhancer of TDP-43-induced toxicity, the method comprising:providing a yeast cell comprising an expression construct comprising a promoter operably linked to a nucleic acid encoding a polypeptide comprising a naturally-occurring TAR DNA-binding protein 43 (TDP-43) protein, wherein the naturally-occurring TDP-43 protein comprises an amino acid sequence that is at least 95% identical to amino acid residues 252-414 of SEQ ID NO:1, wherein expression of the nucleic acid and production of the polypeptide results in a decrease in growth or viability of the cell, wherein the yeast cell has been genetically modified to overexpress a gene;
culturing the yeast cell under conditions that allow for expression of the polypeptide at a level that, in the absence of overexpression of the gene, is sufficient to induce toxicity in the yeast cell;
measuring cell growth or viability in the presence of overexpression of the gene; and
comparing cell growth or viability measured in the presence of overexpression of the gene to cell growth or viability in the absence of overexpression of the gene,
wherein (i) if cell growth or viability is increased in the presence of overexpression of the gene as compared to in the absence of overexpression of the gene, then the gene is identified as a genetic suppressor of TDP-43-induced toxicity, and (ii) if cell growth or viability is decreased in the presence of overexpression of the gene as compared to in the absence of overexpression of the gene, then the gene is identified as a genetic enhancer of TDP-43-induced toxicity.
US Pat. No. 10,426,801

ENCAPSULATED DIAGNOSTICS AND THERAPEUTICS IN NANOPARTICLES—CONJUGATED TO TROPIC CELLS AND METHODS FOR THEIR USE

City of Hope, Duarte, CA...

1. A therapeutic delivery vehicle comprising a gold particle coated with a cationic thiol moiety internalized by a genetically modified neural stem cell, wherein the cationic thiol moiety is 11-mercaptoundecyltrimethylammonium bromide.
US Pat. No. 10,428,337

BRASSICA NAPUS ACC OX PROMOTER IDENTIFIED BY MICROARRAY ANALYSIS

Dow AgroSciences LLC, In...

1. A method for expressing a heterologous coding sequence in a transgenic plant, the method comprising:transforming a plant cell with a gene expression cassette comprising a polynucleotide sequence comprising a sequence identity of at least 98% to SEQ ID NO:1 operably linked to the heterologous coding sequence, which is operably linked to a 3?-untranslated region;
isolating the transformed plant cell comprising the gene expression cassette;
regenerating the transformed plant cell into a transgenic plant; and,
obtaining the transgenic plant, wherein the transgenic plant comprises the gene expression cassette comprising the polynucleotide sequence comprising a sequence identity of at least 98% to SEQ ID NO:1.
US Pat. No. 10,426,802

METHOD FOR PRODUCING SHEET-SHAPED CELL CULTURE

TERUMO KABUSHIKI KAISHA, ...

1. A method for producing a sheet-shaped cell culture, comprising:proliferating myoblast cells;
freezing the proliferated myoblast cells;
thawing the frozen myoblast cells;
forming a sheet-shaped cell culture with the thawed myoblast cells on a culture substrate by seeding the myoblast cells on the culture substrate at a density at which the cells can form a sheet-shaped cell culture substantially without any proliferation on the culture substrate, and wherein the myoblast cells are not proliferated between the freezing of the myoblast cells and the forming of the sheet-shaped cell culture; and
removing the sheet-shaped cell culture from the culture substrate.
US Pat. No. 10,428,338

METHODS AND COMPOSITIONS FOR INCREASING INVERTASE ACTIVITY IN PLANTS

Monsanto Technology LLC, ...

1. A composition comprising: (i) a polynucleotide molecule that comprises at least 18 contiguous nucleotides that are identical or complementary to a plant INVINH1 gene or transcript of said plant gene, wherein said polynucleotide molecule is not operably linked to a promoter or to a viral vector; and, (ii) a transfer agent comprising an organosilicone preparation that conditions a surface of a plant to permeation by the polynucleotide molecule into cells of the plant.
US Pat. No. 10,433,463

BULK AMORPHOUS ALLOY HEAT SINK

Crucible Intellectual Pro...

20. A heat sink comprising:a metal alloy structure of unitary construction comprising:
a first portion comprising a bulk solidifying amorphous alloy having an amorphous phase;
a second portion having a crystalline phase; and
nano- and/or micro-scale features embossed on a surface of the metal alloy structure; wherein
the heat sink is configured to transfer heat by natural convection by air or forced convection by air; and
the crystalline phase is formed along the surface of the metal alloy structure.
US Pat. No. 10,426,803

TOPICAL MEDICAMENT FOR SKIN AND MUCOSAL INJURIES

REV PHARMA CORP, Miami, ...

1. A method for treating epidermolysis bullosa (EB) comprising:a) applying to skin or mucosal surfaces of a patient in need of treatment for EB a dressing gauze or bandage without prior cleaning of said skin or mucosal surfaces, wherein distributed on said dressing is an effective amount of a composition containing: from about 15 to about 30 percent by weight of beeswax; petroleum jelly, cod liver oil, flax seed oil, grape seed oil, chia oil, an added vitamin selected from the group consisting of vitamin A, D and E; and a pharmaceutically acceptable excipient and a preservative;
b) removing said dressing at least twice per day without damaging the patient's skin or mucosal surfaces due to removal of the dressing.
US Pat. No. 10,428,339

SYNTHETIC BRASSICA-DERIVED CHLOROPLAST TRANSIT PEPTIDES

Dow AgroSciences LLC, In...

1. A nucleic acid molecule comprising a polynucleotide that encodes a chimeric protein comprising a synthetic chloroplast transit peptide (CTP) and a linked polypeptide, the amino acid sequence of the synthetic CTP selected from the group consisting of:(A) a first amino acid sequence between 25 and 41 amino acids in length, wherein the first amino acid sequence is at least 90% identical to a contiguous amino acid sequence of the same length in the first 41 amino acids of SEQ ID NO:1, linked to a second amino acid sequence between 25 and 41 amino acids in length, wherein the second amino acid sequence is at least 90% identical to a contiguous amino acid sequence of the same length in the last 41 amino acids of SEQ ID NO:2; and
(B) a first amino acid sequence between 25 and 41 amino acids in length, wherein the first amino acid sequence is at least 90% identical to a contiguous amino acid sequence of the same length in the first 41 amino acids of SEQ ID NO:2, linked to a second amino acid sequence between 25 and 41 amino acids in length, wherein the second amino acid sequence is at least 90% identical to a continuous amino acid sequence of the same length in the last 41 amino acids of SEQ ID NO:1.
US Pat. No. 10,426,804

PENTOSIDINE PRODUCTION INHIBITOR

Kabushiki Kaisha Yakult H...

1. A method for inhibiting pentosidine production in a human subject comprising contacting the human subject with a pentosidine production inhibitor composition that consists of a pharmaceutically acceptable carrier and a fraction of a supernatant, as an active ingredient, obtained from a fermentation product of a cultured medium containing a milk constituent with a lactic acid bacterium as an active ingredient, wherein the fraction has a molecular weight of not more than 20,000 Da,wherein a pentosidine production inhibition rate is 25% or higher when the concentration of the fraction is 0.05% by mass in terms of the dry solid content,
wherein the relative amount of pentosidine in a test sample prepared by combining a sample obtained from the human subject to a solution is determined by fluorescence and the pentosidine production inhibition rate (%) is given by [Math. 1]:
((Ec?Eb)?(Es?Eb))/(Ec?Eb)×100, wherein
Es is the fluorescence intensity of the test sample,
Ec is the fluorescence intensity of the control sample that does not contain pentosidine and contains the same solution as the test sample, and
Eb is the fluorescence intensity of a blank sample that does not include ribose, lysine and arginine.
US Pat. No. 10,428,340

PHYTASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM

Syngenta Participations A...

1. A transgenic plant comprising an isolated, synthetic or recombinant polynucleotide encoding a variant polypeptide of the amino acid sequence of SEQ ID NO: 2, wherein the variant polypeptide comprises at least one amino acid mutation selected from the group consisting of: T48F; T48H; T48I; T48K; T48L; T48M; T48V; T48W; T48Y; L50W; M51A; M51G; M51L; G67A; Y79H; Y79N; Y79S; Y79W; Q86H; P100A; S102A; S102Y; I107H; I107P; I108A; I108Q; I108R; I108S; I108Y; A109V; E113P; L126R; Q137F; Q137L; Q137V; Q137Y; D139Y; P145L; L146R; L146T; F147Y; N148K; N148M; N148R; P149N; L150T; L150Y; K151H; K151P; C155Y; L157C; L157P; V162L; V162T; T163P; L167S; G171M; G171S; S173G; S173H; S173V; I174F; I174P; V191A; L192F; F194L; S197G; S211 H; L216T; P217D; P217G; P217L; P217S; S218I; S218Y; A232P; L235I; A236H; A236T; L244S; Q246W; Q247H; A248L; A248T; P254S; G257A; G257R; H263P; W265L; N266P; L269I; L269T; H272W; A274F; A274I; A274L; A274T; A274V; Q275H; T282H; T291V; T291W; Q309P; P343E; P343I; P343L; P343N; P343R; P343V; N348K; N348W; G353C; Q377R; L379S; L379V; Q381S; S389H; S389V; G395E; G395I; G395L; G395Q; G395T; V422M; I427G; I427S; I427T; and A429P; andwherein the variant polypeptide comprising the at least one amino acid mutation is an amino acid sequence at least 95% identical to the amino acid sequence as set forth in SEQ ID NO:2; and
wherein the variant polypeptide has phytase activity and has decreased gastric stability when compared to the parent polypeptide of the amino acid sequence of SEQ ID NO: 2.
US Pat. No. 10,428,086

SOLVATED CRYSTAL FORM OF RIFAXIMIN, PRODUCTION, COMPOSITIONS AND USES THEREOF

ALFASIGMA S.P.A., Bologn...

1. A stable diethylene glycol monoethyl ether solvate crystalline form of rifaximin ?, wherein the crystalline form has a tetragonal crystal system, the space group is P41212 and the unit cell parameters are a=b=16.51 (1) ?; c=36,80(1) ?; ?=?=?=90°; V=10027(1) ?3 or by a X-ray diffraction spectra with peaks at values of angles 2?±0.1° of 5.9°; 9.0°; 12.9°; 15.4°; 18.8°; 22.8° and 23.4°, wherein the stable diethylene glycol monoethyl ether solvate crystalline form of rifaximin ? does not transform into other forms of rifaximin, and wherein the rifaximin ? has a Cmax value from 0 to 35 ng/ml; AUC0-8 h from 0 to 35 ng·h/ml and AUC0-tlast from 20 to 235 ng·h/ml.
US Pat. No. 10,428,342

P-COUMAROYL-COA:MONOLIGNOL TRANSFERASE

Board of Trustees of Mich...

1. A genetically modified grass plant comprising a feruloyl-CoA: monolignol transferase nucleic acid that encodes a polypeptide with at least 95% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO: 2, 9, 20 and 21 operably linked to a heterologous promoter functional in cells of the plant, which plant has a knockdown or knockout of the grass plant's endogenous p-coumaroyl-CoA: monolignol transferase gene comprising a sequence with at least 95% sequence identity to SEQ ID NO:16 or 18.
US Pat. No. 10,426,807

BONE AND JOINT PROTECTION COMPOSITION AND USE THEREOF

INFINITUS (CHINA) COMPANY...


US Pat. No. 10,428,343

MODIFICATION OF LIGNIN BIOSYNTHESIS VIA SENSE SUPPRESSION

Dairy Australia Limited, ...

1. A method of modifying lignin biosynthesis in a plant, said method including introducing into said plant in a sense orientation an effective amount of a nucleic acid comprising a fragment or variant of a gene encoding caffeic acid O-methyltransferase (COMT), said nucleic acid being capable of modifying lignin biosynthesis in a plant via sense suppression;wherein said fragment or variant comprises a frame shift mutation relative to the gene upon which the fragment or variant is based, resulting in a loss of or at least 50% reduction in enzymatic activity in the COMT; and
wherein said frame shift mutation is a mutation that deletes or inserts one, two, four, five, seven or eight nucleotides within 200 bases of the 5? end of the gene upon which the fragment or variant is based and within a short distance of the ATG start codon of the gene upon which the fragment or variant is based;
such that expression of the gene encoding COMT is suppressed; and
wherein the nucleic acid is selected from the group consisting of SEQ ID Nos: 135, 139, 143, 147, 151, 155, 159, 163, 167 and 171; or
wherein the nucleic acid encodes a polypeptide comprising a sequence selected from the group consisting of SEQ ID Nos: 136, 140, 144, 148, 152, 156, 160, 164, 168 and 172.
US Pat. No. 10,426,808

PLANT EXTRACTS HAVING ANTICOCCIDIAL ACTIVITY

KEMIN INDUSTRIES, INC., ...

1. A method of controlling coccidiosis in animals, comprising the step of administering a plant extract to the animal, said plant extract from a plant selected from the group consisting of Quercus infectoria and Rhus chinensis, said plant extract being administered to the animals in a dose of from about 0.1 to 50 ppm.
US Pat. No. 10,428,344

NUCLEOTIDE SEQUENCES AND CORRESPONDING POLYPEPTIDES CONFERRING MODIFIED PHENOTYPE CHARACTERISTICS IN PLANTS

CERES, INC., Thousand Oa...

1. A method of producing a plant, said method comprising growing a plant cell comprising an exogenous nucleic acid molecule, said exogenous nucleic acid molecule comprising a regulatory region operably linked to a nucleotide sequence encoding a polypeptide, said polypeptide comprising an amino acid sequence having 80 percent or greater sequence identity to the amino acid sequence of SEQ ID NO:5752, and wherein said plant has a difference in the level of low-nitrogen tolerance as compared to the corresponding level of low-nitrogen tolerance of a control plant that does not comprise said nucleic acid molecule.
US Pat. No. 10,426,809

NANOBIOCOMPOSITE FORMULATION FOR WOUND HEALING AND A PROCESS FOR THE PREPARATION THEREOF

1. A nanobiocomposite formulation (NCs) in ointment form comprising silver nanoparticles (AgNPs) and cellulose nanocrystals (CNCs) wherein the ratio of AgNPs and CNCs is in the range of 0.067%-0.4% w/w AgNPs: 7-8% w/w CNCs, and wherein the cellulose is derived from Syzygium cumini leaves.
US Pat. No. 10,428,089

METHOD FOR PRODUCING TRIALKYLGALLIUM COMPOUNDS AND THE USE THEREOF

1. A process for preparing a compound (A), the formulaRGaCl2 or a mixture of RGaCl2 with R2GaCl,
comprising the reaction steps of
a1) reacting gallium with a gaseous alkyl donor in the presence of an activator to form compound (A) at a pressure of 1.1 bar to 10 bar,
a2) and optionally isolating said compound (A) from the reaction mixture,
where R is branched or unbranched alkyl of 1 to 4 carbon atoms and
wherein the activator is selected from the group consisting of R2GaCl, R3Ga2Cl3, RGaCl2 and mixtures thereof, or is a mixture of R2GaCl and RGaCl2, or wherein the reaction product, compound (A), is itself used as activator.
US Pat. No. 10,426,810

TANGERINE PEEL EXTRACT AND ITS PREPARATION AND APPLICATION

Infinitus (China) Company...

1. A method of improving glucose tolerance in an obese person comprising administering an effective amount of a tangerine (Citrus tangerine) peel extract with an acceptable carrier;wherein said tangerine peel extract is free of D-limonene and is prepared by a process comprising
(a) breaking 200 g long-term aged tangerine peel into pieces of 80 mesh;
(b) extracting the pieces of tangerine peels for one hour with supercritical carbon dioxide as an extraction medium at a flow rate of 80 L/h, under a pressure of 35 MPa and at a temperature of 50° C.
US Pat. No. 10,428,346

NUCLEOTIDE SEQUENCES AND CORRESPONDING POLYPEPTIDES CONFERRING MODULATED GROWTH RATE AND BIOMASS IN PLANTS GROWN IN SALINE CONDITIONS

CERES, INC., Thousand Oa...

1. A food or feed product comprising a tissue from a transgenic plant, wherein the transgenic plant and said tissue comprise a recombinant nucleic acid molecule, wherein the recombinant nucleic acid molecule comprises:(a) a nucleotide sequence that encodes a protein comprising the amino acid sequence of SEQ ID NO: 154, and wherein expression of the nucleotide sequence in a plant increases salt stress tolerance as compared to a control plant of the same species lacking said nucleotide sequence;
(b) a nucleotide sequence comprising the polynucleotide sequence of SEQ ID NO: 153, wherein the polynucleotide sequence encodes the protein of SEQ ID NO:154; or
(c) a nucleotide sequence hybridizing to the full length complementary sequence of the nucleotide sequence as set forth in SEQ ID NO: 153 under high stringency conditions which comprise (i) hybridization at 42° C. in 50% formamide, 6×SSC or 6×SSPE, 0.05% Blotto or 5×Denhardt's Reagent, 100 g/ml denatured salmon sperm DNA, 0.05% SDS and washing at 65° C. first in 2×SSC, 0.1% SDS for at least 30 min to one hour and subsequently in 0.1×SSC, 0.5% SDS for at least 30 min to one hour; or (ii) hybridization at 65° C. in 6×SSC or 6×SSPE, 0.05% Blotto or 5×Denhardt's Reagent, 100 ?g/ml denatured salmon sperm DNA, 0.05% SDS and washing at 65° C. first in 2×SSC, 0.1% SDS for at least 30 min to one hour, and subsequently in 0.1×SSC, 0.5% SDS for at least 30 min to one hour and wherein said hybridizing nucleotide sequence encodes a protein which has the functional activity of SEQ ID NO: 154;
wherein said nucleotide sequence is operably linked to a heterologous promoter;
wherein the protein encoded by the nucleotide sequence is expressed in the transgenic plant; and
wherein expression of the protein encoded by said nucleotide sequence in the transgenic plant increases salt stress tolerance as compared to a control plant of the same species that does not comprise the recombinant nucleic acid molecule.
US Pat. No. 10,428,347

HERBICIDE-DETOXIFYING ENZYMES AND USES THEREOF

Spogen Biotech Inc., St....

1. A composition comprising a carrier and an enzyme that comprises an amino acid sequence having 100% identity to SEQ ID NO: 251, wherein:the carrier comprises a preservative, a bactericide or a combination thereof; and/or
the composition further comprises a co-factor regenerating enzyme.
US Pat. No. 10,429,374

GENETICALLY ENCODED POTASSIUM ION INDICATORS

1. A polypeptide comprisinga) a first signaling domain, and
b) a potassium sensor comprising
1) a first domain of the potassium sensor comprising an amino acid sequence which exhibits at least 70% identity to the sequence according to SEQ ID NO: 1; and
2) a second domain of the potassium sensor comprising an amino acid sequence which exhibits at least 70% identity to the sequence according to SEQ ID NO: 2;wherein the potassium sensor is capable of binding positively charged potassium ion and the first signaling domain is capable of generating a detectable signal upon binding of positively charged potassium ion to the potassium sensor, wherein the polypeptide does not consist of SEQ ID NO:3.
US Pat. No. 10,426,812

COMPOSITIONS AND METHODS FOR THE TREATMENT OF ORTHOPEDIC AILMENTS

K.L.R.M., LLC, San Pedro...

1. A method for treatment of bone fractures, loss of bone mineral content or bone density, comprising:administering a pharmaceutically effective amount of a composition over a sufficient period of time that results in an increase in bone formation and/or prevents a decrease in bone mineral density, wherein the composition comprises ginger or a ginger derivative, Muira puama, Paullinia cupana, and at least one of the consisting of L-arginine and L-citrulline that stimulates osteoblasts to increases production of NOS, nitric oxide production and cGMP resulting in bone formation.
US Pat. No. 10,427,068

WATER DISTILLING AND PURIFYING UNIT AND VARIANTS THEREOF

1. A method for distilling water, comprising:moving raw water into an evaporator;
pumping water into a liquid-driven condensing ejector;
discharging water vapor from a vapor outlet of the evaporator into a gas inlet of the condensing ejector;
condensing the water vapor into liquid in the ejector
conducting fluid from an outlet of the ejector into a heat exchanger; and
transferring heat from fluid conducted from the condensing ejector in the heat exchanger to the raw water entering the evaporator, wherein the fluid conducted from the condensing ejector that is pumped into the liquid-driven jet ejector as motive fluid is cooled in the heat exchanger.
US Pat. No. 10,428,092

PROCESS OF PRODUCING PHOSPHINOTHRICIN EMPLOYING NITRILASES

Strategic Enzyme Applicat...

1. An isolated nucleic acid molecule encoding an enzyme having nitrilase activity and catalyzing the hydrolysis of —CN to —COX, wherein X is —OH or —NH2, wherein the nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6.
US Pat. No. 10,428,348

REPRODUCTION OF FEMALE STERILITY LINES AND ITS APPLICATION IN HYBRID SEED PRODUCTION

Exalt State Holdings Limi...

1. A DNA construct, comprising:i) a first nucleotide sequence selected from the group consisting of OsFMS2 gene and OsFMS 1 gene;
ii) a second nucleotide sequence selected from a group consisting of maize ?-amylase gene, auxin gene, rot B gene, cytotoxin gene, diphtherin gene, DAM methylase gene, and PA gene;
iii) a third nucleotide sequence selected from the group consisting of chloromycetin resistance gene, hygromycin resistance gene, streptomycin resistance gene, miramycin resistance gene, sulfonamide resistance gene, glyphosate resistance gene, glufosinate resistance gene, red fluorescence protein gene, cyan fluorescent protein gene, yellow fluorescent protein gene, luciferase gene, green fluorescent protein gene, an anthocyanin p1 gene, and blue fluorescent protein gene, and
at least one regulatory nucleotide sequence that allows expression of the first, the second and the third nucleotide sequences in a plant,
wherein the OsFMS2 gene has a nucleotide sequence selected from the group consisting of SEQ ID NOS:1 and 2, and
wherein the OsFMS1 gene has a nucleotide sequence selected from the group consisting of SEQ ID NOS:17 and 18.
US Pat. No. 10,426,813

METHOD TO ENHANCE ENDURANCE

KYOWA HAKKO BIO CO., LTD....

1. A method of enhancing endurance during exercise of a dehydrated human subject, comprising the step of:administering an effective amount of alanyl-glutamine or a salt thereof to the dehydrated human subject in a single dose,
wherein the dehydrated human subject is at least dehydrated at the beginning of the exercise by a loss of more than 1.5% of the dehydrated human subject's baseline body mass, and
the exercise elicits the dehydrated human subject a workload of at least 75% of the dehydrated human subject's VO2, max.
US Pat. No. 10,427,069

PROCESS FOR UPGRADING BIOMASS DERIVED PRODUCTS USING LIQUID-LIQUID EXTRACTION

Inaeris Technologies, LLC...

1. A method comprising:a) contacting an extraction solvent with a first mixture to form a second mixture comprising an extract and a raffinate, said first mixture comprising process water that has been separated from reaction products comprising (1) bio-oil and (2) said process water, wherein said reaction products are produced from catalytic conversion of biomass at temperatures ranging from 300° C. to 1000° C., and wherein said process water comprises water and biomass derived carbon containing compounds including organics A and organics B, and further wherein:
said organics A comprise compounds selected from the group consisting of i) aldehydes, ii) ketones having from 3 to 4 carbon atoms per molecule, iii) carboxylic acids having from 2 to 3 carbon atoms per molecule, and iv) combinations thereof,
said organics B comprise compounds having at least four carbon atoms per molecule wherein said organics B are substantially free of: i) aldehydes, ii) ketones having from 3 to 4 carbon atoms per molecule, and iii) carboxylic acids having from 2 to 3 carbon atoms per molecule,
said extract and said raffinate are immiscible,
said extract comprises substantially all of said extraction solvent and substantially all of said organics B,
said raffinate comprises substantially all of said water and substantially all of said organics A, and
said extraction solvent has a dipole moment greater than about 1.0 debye, a density less than about 1.0, a water solubility at 20° C. of less than about 2.5 g/100 ml of water, and a boiling point in the range of from about 90 to about 300° F.;
b) separating said second mixture thereby forming an intermediate product stream comprising at least a portion of said extract and a waste water stream comprising substantially all of said raffinate, wherein said wastewater stream comprises less than about 0.5 wt % of said organics B; and
c) removing at least a portion of said extraction solvent from said intermediate product stream forming a recovered extraction solvent and a bio-oil product.
US Pat. No. 10,428,093

LIPID CO-FACTOR ESSENTIAL FOR CELL DENSITY SIGNALING

1. An isolated tissue-specific lipid co-factor having a formula C63H123N2O11P and a mass of about 1114.89 MW, said lipid cofactor binds to a polypeptide factor that comprises the amino acid sequence set forth in SEQ ID NO: 3 or SEQ ID NO: 5 to form a protein/lipid cell density signaling complex, said cell density signally complex controlling cell proliferation, differentiation or apoptosis in bone and cartilage tissue, and said lipid co-factor comprising a ceramide phosphate, a glycerol lipid with a single fatty acid, and a linker.
US Pat. No. 10,428,349

MULTIMERIC CODING NUCLEIC ACID AND USES THEREOF

Translate Bio, Inc., Lex...

1. A method of delivering a multimeric coding nucleic acid (MCNA) for in vivo protein production, comprising administering to a subject in need of the MCNA, wherein the MCNA comprises two messenger RNAs (mRNAs) linked at 3? ends, via a stable linkage, such that the multimeric coding nucleic acid has two 5? ends, and wherein the stable linkage is an oligonucleotide bridge comprising an internal 3?-to-3? inverted phosphodiester linkage.
US Pat. No. 10,426,814

CHEMICAL REPROGRAMMING OF HUMAN GLIAL CELLS INTO NEURONS FOR BRAIN AND SPINAL CORD REPAIR

The Penn State Research F...

1. A method for generating neurons in the brain of an individual, wherein the individual is a mammal, comprising administering to the individual a combination of compounds that comprise at least four of compounds or functional analogs thereof or pharmaceutically acceptable salts thereof, wherein the compounds are:i) LDN193189
ii) CHIR99021,
iii) N-[(3,5-Difluorophenyl)acetyl]-L-alany-2-phenyl]glycine-I,1-methylethyl ester (DAPT), and
iv) SB431542,wherein the administering the compounds is cell and virus free, and wherein the administering is sufficient such that the neurons are generated.
US Pat. No. 10,428,350

METHODS AND COMPOSITIONS FOR THE ACTIVATION OF GAMMA-DELTA T-CELLS

American Gene Technologie...

1. A method of treating a cancer in a subject in need thereof, the method comprising administering or having administered a therapeutically-effective amount of an immunotherapy-based composition to the subject, wherein the immunotherapy-based composition is obtained from an immunotherapy-based viral delivery system comprising:(i) at least one helper plasmid comprising DNA sequences for expressing a functional protein derived from each of a gag, pol, and rev gene;
(ii) an envelope plasmid comprising a DNA sequence for expressing an envelope protein capable of infecting a target cell; and
(iii) a therapeutic vector comprising:
at least one encoded shRNA that, when expressed, inhibits production of farnesyl diphosphate synthase (FDPS) or,
at least one encoded microRNA that, when expressed, inhibits production of farnesyl diphosphate synthase (FDPS).
US Pat. No. 10,426,815

PREVENTION AND TREATMENT OF ITCH WITH AN MRGPR ANTAGONIST

The General Hospital Corp...

1. A method of preventing or treating itch or treating a disease or disorder having itch as a symptom or sensation associated with a disease or disorder in a subject, the method comprising administering a therapeutically effective amount of an MRG receptor antagonist to the subject, wherein the MRG receptor antagonist is a tri-peptide QWF (Gln-Trp-Phe) or an analog or a derivative thereof.
US Pat. No. 10,428,351

METHODS FOR TRANSDUCTION AND CELL PROCESSING

Juno Therapeutics, Inc., ...

1. A transduction method, the method comprising incubating, in an internal cavity of a centrifugal chamber, an input composition comprising cells and viral particles containing a recombinant viral vector, wherein:the centrifugal chamber comprises:
an end wall, a substantially rigid side wall extending from said end wall, and one or more opening, wherein at least a portion of said side wall surrounds said internal cavity and at least one of the one or more opening is capable of permitting intake of liquid or gas into said internal cavity and expression of liquid or gas from said cavity; and
a movable member capable of moving within the chamber to vary the internal volume of the internal cavity, whereby the internal cavity is a cavity of variable volume defined by said end wall, said substantially rigid side wall, and said movable member;
the centrifugal chamber is rotatable around an axis of rotation and is rotating around said axis of rotation during at least a portion of the incubation;
during at least a portion of the incubation in the chamber or during the rotation of the chamber, the liquid volume of the input composition occupies only a portion of the volume of the internal cavity of the chamber, the volume of the cavity during said at least a portion or during said rotation further comprising a gas; wherein prior to or during said incubation, effecting movement of the movable member and effecting intake of the gas into said internal cavity, thereby increasing the volume of the internal cavity of the chamber; and
wherein the method generates an output composition comprising a plurality of the cells transduced with the viral vector.
US Pat. No. 10,428,352

METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION

The Regents of the Univer...

1. A method of targeting and binding a target DNA in a prokaryotic cell, the method comprising:contacting the target DNA inside of the prokaryotic cell with:
(a) a Cas9 protein; and
(b) a single molecule DNA-targeting RNA comprising, in 5? to 3? order:
(i) a targeter-RNA comprising a nucleotide sequence that is complementary to, and hybridizes with, a target sequence of the target DNA; and
(ii) an activator-RNA that hybridizes with the targeter-RNA to form a double-stranded RNA duplex,
wherein (i) and (ii) are covalently linked by intervening nucleotides,
wherein the Cas9 protein and the single molecule DNA-targeting RNA form a complex that binds to the target DNA.
US Pat. No. 10,429,379

AUTOANTIGENS FOR DIAGNOSIS OF RHEUMATOID ARTHRITIS

THE GENERAL HOSPITAL CORP...

1. A method of treating rheumatoid arthritis in a subject comprising:(a) receiving the results of an assay that indicates an increase in the level of IFN? secretion and/or T cell proliferation following contact of a biological sample from the subject with one or more of filamin-A and N-acetylglucosamine-6-sulfatase whole protein or polypeptide fragments compared with an appropriate control sample; or
(b) receiving the results of an assay that indicates an increase in the level of immunocomplexes following contact of a biological sample from the subject with one or more of filamin-A and N-acetylglucosamine-6-sulfatase, whole protein or polypeptide fragments compared to an appropriate control sample; and
(c) administering to the subject one or more of a nonsteroidal anti-inflammatory drug (NSAIDs), a steroid, a disease modifying anti-rheumatic drug (DMARD), adalimumab, etanercept, abatacept, anakinra, cimzia, golimumab, infliximab, tocilizumab and tofacitinib.
US Pat. No. 10,426,817

TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND OTHER EYE DISEASES WITH APOLIPOPROTEIN MIMETICS

MacRegen, Inc., San Jose...

1. A method of treating age-related macular degeneration (AMD), comprising administering to a human subject afflicted with AMD a therapeutically effective amount of an apolipoprotein (apo) mimetic, wherein the apo mimetic is administered locally to, into, in or around the eye in a total dose from 1 mg±10% to 10 mg±10% over a period of 6 months.
US Pat. No. 10,428,353

PRODUCTION OF PRODUCTS WITH FAVOURABLE GHG EMISSION REDUCTIONS FROM CELLULOSIC FEEDSTOCKS

Iogen Corporation, Ottaw...

1. A process for producing a transportation or heating fuel comprising the steps of:(i) treating a cellulosic feedstock in one or more processing steps that release extractives comprising acetic acid, acetate or a combination thereof from the feedstock;
(ii) conducting a solids-liquid separation on a process stream comprising the extractives and solids, thereby producing an aqueous stream comprising the extractives and a solids stream comprising insoluble components;
(iii) feeding at least a portion of the aqueous stream comprising one or more of the extractives to an anaerobic digester to produce a crude biogas that comprises carbon dioxide;
(iv) removing at least 80 wt % of the carbon dioxide present in the crude biogas to produce a purified biogas;
(v) carrying out or causing one or more parties to carry out a process comprising subjecting solids from at least one stream selected from the solids stream comprising the insoluble components and a stream derived therefrom to a thermal process to produce a fuel or fuel intermediate;
(vi) introducing the purified biogas produced in step (iv) to a pipeline and causing withdrawal of an amount of methane from said pipeline corresponding to an amount of the purified biogas introduced to the pipeline;
(vii) providing one or more products obtained or derived from step (v), step (vi) or a combination thereof for use as a transportation or heating fuel; and
(viii) generating or causing generation of a renewable fuel credit with respect to said one or more products.
US Pat. No. 10,426,818

METHOD AND PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF DIABETES

INSERM (Institut National...

1. A method for treating type 2 diabetes comprisingadministering to a human subject in need thereof a therapeutically effective amount of (Pyr1)-apelin-13.
US Pat. No. 10,428,098

PROCESSES FOR PREPARING AND USING RUTHENIUM AND OSMIUM COMPLEXES

Johnson Matthey Public Li...

2. A process for preparing an [M(Y)2(L)2(L2)] complex, the process comprising the step of:reacting an [M(Y)2(L)2] complex with L2 in a polar aprotic solvent;
wherein:
M is ruthenium or osmium;
Y is a carboxylate ligand;
L is a monodentate phosphorus ligand; and
L2 is a bidentate N,N ligand comprising two nitrogen-containing groups.
US Pat. No. 10,428,354

ALTERED HOST CELL PATHWAY FOR IMPROVED ETHANOL PRODUCTION

DANISCO US INC, Palo Alt...

1. A recombinant yeast cell comprising at least one heterologous nucleic acid encoding one or more polypeptide having:i) phosphoketolase activity;
ii) phosphotransacetylase activity; and
iii) acetylating acetaldehyde dehydrogenase activity,
wherein said cell does not comprise a heterologous modified xylose reductase gene,
wherein said cell is capable of increased ethanol production from glucose in a fermentation process when compared to the yeast cell without the at least one heterologous nucleic acid, and
wherein the polypeptide having phosphoketolase activity has the amino acid of SEQ ID NO: 57, the polypeptide having acetylating acetaldehyde dehydrogenase activity has the amino acid of SEQ ID NO: 32, and the polypeptide having phophotransacetylase activity is the phophotransacetylase from Lactobacillus plantarum.